+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06770439

Phase II Study of IBI343 With Chemotherapy for Advanced CLDN18.2-Positive Pancreatic Cancer

Led by Zhejiang University · Updated on 2025-09-23

64

Participants Needed

2

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of IBI343 combined with chemotherapy in patients with advanced pancreatic cancer that tests positive for CLDN18.2. This phase II study includes two parts Part 1 is a safety lead-in phase enrolling patients who may or may not have received prior systemic therapy, and Part 2 is an extension phase involving a randomized comparison. The study aims to better understand treatment options for this serious condition using a combination approach. In Part 1, patients receive IBI343 combined with an AG chemotherapy regimen consisting of albumin-bound paclitaxel and gemcitabine given by intravenous infusion on days 1 and 8 every 3 weeks. Dose adjustments will be made based on safety observations before moving to Part 2. In Part 2, 40 patients will be randomly assigned to two groups Arm A will receive IBI343 plus gemcitabine and albumin-bound paclitaxel at doses to be determined, and Arm B will receive a standard chemotherapy regimen of gemcitabine and albumin-bound paclitaxel at fixed doses on days 1 and 8 every 3 weeks. Participants will be monitored for treatment response, side effects, and overall survival up to two years. Assessments include measuring tumors using imaging and tracking adverse events. The main outcomes are objective response rate and safety, with additional measures such as progression-free survival and duration of response. The study involves regular visits for treatment and evaluation, with ongoing monitoring to understand the effects of the combination therapy over time.

CONDITIONS

Brief Title

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

Research Team

T

Tingbo Liang, MD.

Y

Yiwen Chen, MD.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here